Tirdzniecība Black Diamond Therapeutics, Inc. - BDTX CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.0468 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.025457% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.003235% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Black Diamond Therapeutics Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 2.1368 |
| Atvērt* | 2.2067 |
| Izmaiņas par 1 gadu* | 32.14% |
| Dienas Diapazons* | 2.1069 - 2.3365 |
| 52 ned Diapazons | 1.18-4.08 |
| Vidējais apjoms (10 dienas) | 68.26K |
| Vidējais apjoms (3 mēneši) | 1.70M |
| Tirgus Kapitalizācija | 78.50M |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 36.51M |
| Ieņēmumi | N/A |
| EPS | -2.38 |
| Dividende (Ienesīgums %) | N/A |
| Beta | 1.86 |
| Nākamās Peļņas Datums | Aug 7, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Jun 2, 2023 | 2.3266 | 0.1399 | 6.40% | 2.1867 | 2.3665 | 2.0969 |
| Jun 1, 2023 | 2.1368 | 0.3295 | 18.23% | 1.8073 | 2.1668 | 1.7973 |
| May 31, 2023 | 1.8373 | 0.0300 | 1.66% | 1.8073 | 1.8572 | 1.7973 |
| May 30, 2023 | 1.8572 | 0.0999 | 5.68% | 1.7573 | 1.8772 | 1.7573 |
| May 26, 2023 | 1.7673 | 0.0699 | 4.12% | 1.6974 | 1.7774 | 1.6575 |
| May 25, 2023 | 1.7274 | 0.0699 | 4.22% | 1.6575 | 1.7574 | 1.6575 |
| May 24, 2023 | 1.6974 | 0.0100 | 0.59% | 1.6874 | 1.7374 | 1.6375 |
| May 23, 2023 | 1.6775 | -0.1298 | -7.18% | 1.8073 | 1.8672 | 1.6774 |
| May 22, 2023 | 1.8373 | 0.0899 | 5.14% | 1.7474 | 1.8772 | 1.7474 |
| May 19, 2023 | 1.7773 | 0.0699 | 4.09% | 1.7074 | 1.7873 | 1.6175 |
| May 18, 2023 | 1.5976 | -0.0998 | -5.88% | 1.6974 | 1.6975 | 1.5576 |
| May 17, 2023 | 1.7074 | -0.0400 | -2.29% | 1.7474 | 1.7674 | 1.6774 |
| May 16, 2023 | 1.7673 | -0.1198 | -6.35% | 1.8871 | 1.9171 | 1.7673 |
| May 15, 2023 | 1.9171 | 0.1198 | 6.67% | 1.7973 | 1.9271 | 1.7573 |
| May 12, 2023 | 1.8672 | -0.0399 | -2.09% | 1.9071 | 1.9071 | 1.8073 |
| May 11, 2023 | 1.9171 | 0.1098 | 6.08% | 1.8073 | 1.9970 | 1.7973 |
| May 10, 2023 | 1.8472 | 0.0499 | 2.78% | 1.7973 | 1.8972 | 1.7973 |
| May 9, 2023 | 1.8173 | 0.0400 | 2.25% | 1.7773 | 1.8173 | 1.6575 |
| May 8, 2023 | 1.9072 | 0.0300 | 1.60% | 1.8772 | 1.9371 | 1.8572 |
| May 5, 2023 | 1.9571 | 0.2097 | 12.00% | 1.7474 | 2.0170 | 1.7374 |
Black Diamond Therapeutics, Inc. Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| Friday, June 9, 2023 | ||
| Laiks (UTC) (UTC) 16:45 | Valsts US
| Notikums Black Diamond Therapeutics Inc at Jefferies Healthcare Conference Black Diamond Therapeutics Inc at Jefferies Healthcare ConferenceForecast -Previous - |
| Monday, August 7, 2023 | ||
| Laiks (UTC) (UTC) 12:30 | Valsts US
| Notikums Q2 2023 Black Diamond Therapeutics Inc Earnings Release Q2 2023 Black Diamond Therapeutics Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Laiks (UTC) (UTC) 13:30 | Valsts US
| Notikums Q3 2023 Black Diamond Therapeutics Inc Earnings Release Q3 2023 Black Diamond Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 0 | 0 | 0 | 0 | 0 |
| Kopējie Darbības Izdevumi | 92.828 | 126.872 | 69.57 | 29.332 | 8.904 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 28.391 | 30.043 | 21.361 | 7.579 | 1.954 |
| Pētniecība un Attīstība | 64.437 | 96.829 | 48.209 | 21.753 | 6.95 |
| Neparedzēti Izdevumi (Ienākumi) | 0 | ||||
| Darbības Izdevumi | -92.828 | -126.872 | -69.57 | -29.332 | -8.904 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -0.219 | 3.464 | 4.041 | -5.932 | -0.011 |
| Citi, Neto | -0.354 | -2.188 | -1.725 | 0.006 | -0.016 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Neto Ienākumi | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Atšķaidītie Neto Ienākumi | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Atšķaidītie Ienākumi par Akcijām | 36.3256 | 36.189 | 32.9071 | 32.6364 | 32.6364 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -2.50977 | -3.47056 | -2.04375 | -1.08033 | -0.27365 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| Atšķaidītā Normalizētā Peļņa par Akciju | -2.57122 | -3.47056 | -2.04375 | -1.08033 | -0.27365 |
| Gain (Loss) on Sale of Assets | 2.232 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 0 | 0 | 0 | 0 | 0 |
| Kopējie Darbības Izdevumi | 21.561 | 21.852 | 22.124 | 23.173 | 25.679 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 6.808 | 7.243 | 6.277 | 6.978 | 7.893 |
| Pētniecība un Attīstība | 14.753 | 14.609 | 15.847 | 16.195 | 17.786 |
| Darbības Izdevumi | -21.561 | -21.852 | -22.124 | -23.173 | -25.679 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 0.622 | -1.573 | 0.562 | 0.386 | 0.406 |
| Citi, Neto | 0.064 | 0.115 | -0.092 | -0.143 | -0.234 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Neto Ienākumi | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Atšķaidītie Neto Ienākumi | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Atšķaidītie Ienākumi par Akcijām | 36.4839 | 36.3902 | 36.3462 | 36.2939 | 36.2713 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.57217 | -0.57922 | -0.59577 | -0.63179 | -0.70323 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.57217 | -0.64056 | -0.59577 | -0.63179 | -0.70323 |
| Gain (Loss) on Sale of Assets | 2.232 |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 127.706 | 215.703 | 319.554 | 155.714 | 51.684 |
| Nauda un Īstermiņa Ieguldījumi | 122.807 | 209.786 | 315.067 | 154.666 | 51.66 |
| Nauda un Ekvivalenti | 34.315 | 65.799 | 34.605 | 154.666 | 51.66 |
| Prepaid Expenses | 4.899 | 5.917 | 4.487 | 1.048 | 0.024 |
| Total Assets | 156.255 | 247.682 | 329.67 | 158.295 | 51.826 |
| Property/Plant/Equipment, Total - Net | 27.381 | 30.74 | 8.787 | 0.164 | 0.134 |
| Property/Plant/Equipment, Total - Gross | 28.131 | 31.109 | 8.951 | 0.276 | 0.234 |
| Accumulated Depreciation, Total | -0.75 | -0.369 | -0.164 | -0.112 | -0.1 |
| Other Long Term Assets, Total | 1.168 | 1.239 | 1.329 | 2.417 | 0.008 |
| Total Current Liabilities | 15.261 | 23.642 | 14.218 | 4.863 | 2.575 |
| Accounts Payable | 1.877 | 4.107 | 2.538 | 1.964 | 0.416 |
| Accrued Expenses | 13.384 | 19.535 | 11.68 | 2.899 | 0.452 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 1.707 | |||
| Total Liabilities | 40.56 | 51.782 | 21.912 | 4.879 | 6.598 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 25.299 | 28.14 | 7.694 | 0.016 | 4.023 |
| Total Equity | 115.695 | 195.9 | 307.758 | 153.416 | 45.228 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 60.77 | ||
| Common Stock | 0.005 | 0.005 | 0.005 | 0.001 | 0.001 |
| Additional Paid-In Capital | 452.503 | 440.129 | 425.363 | 3.812 | 0.169 |
| Retained Earnings (Accumulated Deficit) | -334.989 | -243.82 | -118.224 | -50.97 | -15.712 |
| Total Liabilities & Shareholders’ Equity | 156.255 | 247.682 | 329.67 | 158.295 | 51.826 |
| Total Common Shares Outstanding | 36.4343 | 36.2346 | 36.0784 | 32.6364 | 32.6364 |
| Redeemable Preferred Stock | 0 | 0 | 200.573 | ||
| Īstermiņa Ieguldījumi | 88.492 | 143.987 | 280.462 | ||
| Other Equity, Total | -0.414 | 0.614 | |||
| Unrealized Gain (Loss) | -1.824 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 107.977 | 127.706 | 150.978 | 168.558 | 188.304 |
| Nauda un Īstermiņa Ieguldījumi | 103.366 | 122.807 | 144.181 | 160.89 | 179.739 |
| Nauda un Ekvivalenti | 39.141 | 34.315 | 53.96 | 55.877 | 54.081 |
| Īstermiņa Ieguldījumi | 64.225 | 88.492 | 90.221 | 105.013 | 125.658 |
| Prepaid Expenses | 4.611 | 4.899 | 6.797 | 7.668 | 8.565 |
| Total Assets | 135.582 | 156.255 | 180.416 | 198.834 | 219.482 |
| Property/Plant/Equipment, Total - Net | 26.437 | 27.381 | 28.27 | 29.098 | 29.945 |
| Property/Plant/Equipment, Total - Gross | 27.282 | 28.131 | 28.98 | 29.681 | 30.439 |
| Accumulated Depreciation, Total | -0.845 | -0.75 | -0.71 | -0.583 | -0.494 |
| Other Long Term Assets, Total | 1.168 | 1.168 | 1.168 | 1.178 | 1.233 |
| Total Current Liabilities | 12.847 | 15.261 | 21.143 | 19.706 | 19.469 |
| Accounts Payable | 3.046 | 1.877 | 5.76 | 2.222 | 1.883 |
| Accrued Expenses | 9.801 | 13.384 | 15.383 | 17.484 | 17.586 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 37.392 | 40.56 | 47.185 | 46.463 | 46.922 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 24.545 | 25.299 | 26.042 | 26.757 | 27.453 |
| Total Equity | 98.19 | 115.695 | 133.231 | 152.371 | 172.56 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.005 | 0.005 | 0.005 | 0.005 | 0.005 |
| Additional Paid-In Capital | 455.225 | 452.503 | 449.625 | 446.909 | 443.657 |
| Retained Earnings (Accumulated Deficit) | -355.864 | -334.989 | -313.911 | -292.257 | -269.327 |
| Other Equity, Total | -1.176 | -1.824 | -2.488 | -2.286 | -1.775 |
| Total Liabilities & Shareholders’ Equity | 135.582 | 156.255 | 180.416 | 198.834 | 219.482 |
| Total Common Shares Outstanding | 36.512 | 36.4343 | 36.3662 | 36.3157 | 36.2876 |
| Redeemable Preferred Stock |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Nauda no Darbības | -85.082 | -100.148 | -52.146 | -24.674 | -8.454 |
| Nauda no Darbības | 0.508 | 0.205 | 0.052 | 0.047 | 0.044 |
| Bezskaidras Naudas Preces | 15.48 | 18.223 | 10.014 | 10.074 | 0.079 |
| Izmaiņas Apgrozāmajā Kapitālā | -9.901 | 7.02 | 5.042 | 0.463 | 0.354 |
| Nauda no Ieguldījumu Darbībām | 53.366 | 130.613 | -281.691 | -0.021 | -0.076 |
| Kapitālie Izdevumi | -0.192 | -2.71 | -0.142 | -0.021 | -0.076 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 53.558 | 133.323 | -281.549 | 0 | |
| Nauda no Darbībām ar Finansēšanu | 0.177 | 0.729 | 214.944 | 127.756 | 52.312 |
| Naudas Plūsma Finansēšanas Posteņos | 0 | -1.743 | 0 | ||
| Akciju Izsniegšana (Atkāpšanās), Neto | 0.177 | 0.729 | 214.944 | 129.499 | 52.312 |
| Parādu Izsniegšana (Atkāpšanās), Neto | 0 | ||||
| Neto Izmaiņas Naudā | -31.539 | 31.194 | -118.893 | 103.061 | 43.782 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -20.875 | -91.169 | -70.091 | -48.437 | -25.507 |
| Cash From Operating Activities | -20.031 | -85.082 | -63.143 | -46.667 | -28.6 |
| Cash From Operating Activities | 0.122 | 0.508 | 0.382 | 0.253 | 0.125 |
| Non-Cash Items | 3.507 | 15.48 | 11.804 | 8.366 | 4.293 |
| Changes in Working Capital | -2.785 | -9.901 | -5.238 | -6.849 | -7.511 |
| Cash From Investing Activities | 24.806 | 53.366 | 51.044 | 36.537 | 16.729 |
| Capital Expenditures | 0 | -0.192 | -0.192 | -0.2 | -0.007 |
| Other Investing Cash Flow Items, Total | 24.806 | 53.558 | 51.236 | 36.737 | 16.736 |
| Cash From Financing Activities | 0.051 | 0.177 | 0.205 | 0.153 | 0.153 |
| Issuance (Retirement) of Stock, Net | 0.051 | 0.177 | 0.205 | 0.153 | 0.153 |
| Net Change in Cash | 4.826 | -31.539 | -11.894 | -9.977 | -11.718 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| Versant Ventures | Venture Capital | 17.6634 | 6449348 | 0 | 2023-03-15 | LOW |
| Bellevue Asset Management AG | Investment Advisor | 14.778 | 5395839 | -5000 | 2023-03-31 | LOW |
| New Enterprise Associates (NEA) | Venture Capital | 9.4454 | 3448757 | 0 | 2023-03-31 | LOW |
| RA Capital Management, LP | Hedge Fund | 7.0932 | 2589904 | 0 | 2023-03-31 | LOW |
| Boxer Capital, L.L.C. | Hedge Fund | 5.5183 | 2014858 | 0 | 2023-03-31 | LOW |
| Invus Public Equities Advisors, LLC | Investment Advisor | 4.5095 | 1646517 | 0 | 2023-03-31 | LOW |
| EcoR1 Capital, LLC | Hedge Fund | 3.2621 | 1191094 | 908963 | 2023-03-31 | LOW |
| Epstein (David M) | Individual Investor | 2.5703 | 938479 | 0 | 2023-03-15 | LOW |
| Millennium Management LLC | Hedge Fund | 2.1269 | 776594 | 252037 | 2023-03-31 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.0749 | 757585 | 0 | 2023-03-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 1.5276 | 557771 | -216027 | 2023-03-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.4344 | 523719 | -127676 | 2023-03-31 | LOW |
| Verition Fund Management LLC | Hedge Fund | 0.943 | 344307 | 344307 | 2023-03-31 | HIGH |
| Newtyn Management, LLC | Hedge Fund | 0.8397 | 306609 | -8391 | 2023-03-31 | MED |
| Two Sigma Investments, LP | Hedge Fund | 0.7769 | 283654 | -72510 | 2023-03-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7406 | 270428 | 5138 | 2023-03-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.5957 | 217500 | -3113 | 2023-03-31 | HIGH |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.5023 | 183398 | -102283 | 2023-03-31 | LOW |
| BioImpact Capital LLC | Investment Advisor/Hedge Fund | 0.3968 | 144888 | 0 | 2023-03-31 | LOW |
| Tekla Capital Management LLC | Investment Advisor | 0.3615 | 131990 | 0 | 2023-03-31 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group535K+
Tirgotāji
87K+
Ikmēneša aktīvie klienti
$113M+
Ikmēneša ieguldījumu apjoms
$64M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Black Diamond Therapeutics, Inc. Company profile
Par Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. ir precīzijas onkoloģijas medicīnas uzņēmums. Uzņēmums koncentrējas uz mazu molekulu, MasterKey terapiju atklāšanu un izstrādi. Uzņēmums izstrādā mazmolekulāru kināžu inhibitoru klāstu, kas ir vērsti pret dažādām vēža ierosinātāju mutācijām. Uzņēmuma tehnoloģiskā platforma, mutāciju-alosterijas-farmakoloģijas (MAP) platforma, ir izstrādāta tā, lai ļautu analizēt populācijas līmeņa ģenētiskās sekvencēšanas datus, lai atklātu onkogēnās mutācijas, kas veicina vēzi dažādos audzēju veidos. Tās vadošais kandidātprodukts BDTX-189 ir izstrādāts kā perorāli pieejams, neatgriezenisks mazmolekulārs inhibitors, kas ir vērsts pret 48 nekanoniskām un kanoniskām ErbB kināzes epidermālā augšanas faktora receptora (EGFR) un HER2 vadošo mutāciju spektru. BDTX-1535 ir inhibitors, kas iedarbojas uz EGFR mutāciju spektru, ieskaitot alosteriskās un kanoniskās mutācijas. Tam ir arī agrīnas stadijas programmas, piemēram, pret B-Raf proto-onkogēnu (BRAF) un fibroblastu augšanas faktora receptoru (FGFR).
| Industry: | Bio Therapeutic Drugs |
One Main Street, 14th Floor
CAMBRIDGE
MASSACHUSETTS 02142
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 535 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com